Mental Health Solutions Stocks
Specialized clinical providers and biopharmaceutical developers focus on the diagnosis, inpatient management, and pharmacological treatment of psychiatric and neurological disorders. Revenue models vary from fee-for-service facility operations and government-contracted behavioral health programs to high-risk, high-reward drug discovery targeting the central nervous system.
As of Oct 23, 2026, Mental Health Solutions has 37 US-listed companies worth $51.7B combined. The median member moved -1.3% over the past week; MYGN led among the 25 largest at +46.2% and DRIO trailed at -21.8%.
Companies in Mental Health Solutions
- UHS – Universal Health Services Inc, $11B
- AXSM – Axsome Therapeutics Inc, $7.6B
- HIMS – Hims Hers Health Inc, $6.8B
- LFST – Lifestance Health Group Inc, $4.6B
- DFTX – Definium Therapeutics, Inc., $4.4B
- INDV – Indivior PLC Ordinary Shares, $4.2B
- ACHC – Acadia Healthcare Company Inc, $2.9B
- SUPN – Supernus Pharmaceuticals Inc, $2.4B
- CMPS – Compass Pathways Plc, $1.6B
- GHRS – GH Research PLC, $1.3B
- TDOC – Teladoc Inc, $1B
- ANRO – Alto Neuroscience, Inc., $956M
- HELP – Cybin Inc., $799M
- BWAY – Brainsway Ltd, $474M
- MPLT – MapLight Therapeutics, Inc. Common Stock, $458M
- MYGN – Myriad Genetics Inc, $396M
- STIM – Neuronetics Inc, $162M
- NRXP – NRX Pharmaceuticals Inc, $113M
- NERV – Minerva Neurosciences Inc, $112M
- NMRA – Neumora Therapeutics, Inc., $89.4M
- DRIO – DarioHealth Corp, $56.8M
- IXHL – Incannex Healthcare Inc., $40.3M
- MIRA – MIRA Pharmaceuticals, Inc. Common Stock, $28M
- OPTH – Optimi Health Corp. Common Shares, $23.6M
- AYTU – Aytu BioScience Inc, $21.3M
- PBM – Psyence Biomedical Ltd. Common Shares, $19.1M
- LPCN – Lipocine Inc, $16.9M
- QNTM – Quantum BioPharma Ltd., $14.6M
- SYRA – Syra Health Corp. Class A Common Stock, $12.2M
- VTGN – VistaGen Therapeutics Inc, $8.9M
- ENVB – Enveric Biosciences Inc, $6.2M
- NXL – Nexalin Technology Inc., $3.8M
- CMND – Clearmind Medicine Inc. Common Shares, $3.3M
- SILO – Silo Pharma Inc, $2.5M
- BTAI – BioXcel Therapeutics Inc, $2.3M
- PTIX – Protagenic Therapeutics, $1.4M
- SOBR – Sobr Safe Inc, $266,666